Global Scans · Respect · Weekly Summary

• [New] A coalition of EU member states could suspend licence recognition for American cryptocurrency platforms. European Council on Foreign Relations
• [New] By the end of 2026, most U.S. international terminals will board passengers using facial recognition instead of paper or digital boarding passes. Idyllic Pursuit
• [New] The Middle East and Africa are expected to have steady growth over the forecast years, driven by increasing investments in technology and a growing recognition of AI's use across various sectors. Precedence Research
• [New] Commercial trial operations are expected by early 2029, subject to certification and regulatory approval. / Kazakhstan Euronews
• [New] From the Dubai Land Department putting title deeds on blockchain and launching real estate tokenization from as little as AED 2,000, to the Dubai 2040 Urban Master Plan reshaping where value will grow, innovation is becoming a real driver of long-term appreciation. RHK Properties
• [New] Despite Trump's executive order aiming to streamline access to psychedelic medicines, and an anticipated FDA approval decision on Compass Pathways' synthetic psilocybin compound, COMP360, expected in late 2026 or early 2027, progress has ground to a halt. Psychedelics Today
• [New] Potentially, if policy starts to favour national champions or politically important industries at the expense of returns on capital, it could pull against the reforms that have made Japan more attractive to overseas investors. TrustNet
• [New] The fingerprint recognition segment will exhibit at a CAGR of around 22.6% from 2022 to 2032. Persistence Market Research
• [New] Fingerprint recognition is expected to remain the most commonly used technology globally. Persistence Market Research
• [New] The Worldpay report forecasts a decline in the share of credit card payments at U.S. brick-and-mortar stores as digital wallets gain popularity. The Ohio Society of CPAs
• [New] Policy recommendations from the Federation of American Scientists emphasize risk-tiered AI approval and independent review for high-consequence deployments, a standard that regulators in multiple jurisdictions are moving toward. Heightscg
• [New] A treatment made by Regeneron Pharmaceuticals could be the first gene therapy for deafness to earn approval from the FDA. Live Science

Last updated: 22 June 2026